Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Start Your Discovery Campaign on the Right Foot
The quality of an antigen is critical to the success of every in vivo antibody discovery project. We built our antigen production capabilities to offer a reliable source of high-quality reagents and give our partners flexibility without sacrificing a streamlined workflow.
Twist’s Molecular Biology team has years of experience generating reagents for antibody discovery campaigns. We have optimized and proprietary techniques that generate robust immune responses for difficult target classes. Additionally, we can leverage our proprietary DiversimAb™ platform to induce immune responses against poorly immunogenic targets and improve antibody discovery timelines and success rates.
Immunization Expertise for any Antigen
Immunization Expertise for any Antigen
Ce que les scientifiques ont à dire
Title
ROBERT CARNAHAN, PHD
Title
Twist est le seul fournisseur d'ADN synthétique capable de livrer rapidement la quantité et la qualité d'ADN dont nous avons besoin pour nos projets. Nous travaillons avec eux non seulement en tant que fournisseur de gènes et d'anticorps synthétiques, mais nous avons aussi élargi notre collaboration pour profiter des capacités de Twist Biopharma qui, selon nous, complètent nos travaux de recherche d'anticorps.
ROBERT CARNAHAN,, PHD
Directeur associé du Vanderbilt Vaccine Center
Notre plateforme génère et valide rapidement de nouvelles cibles pour le traitement de cancers difficiles. Working with Abveris will enable us to quickly identify and select highly specific antibodies for those targets, so that we can take the best antibody forward to address the needs of particular patient populations.
JEFF GOLDBERG,, CEO
Immunitas Therapeutics
Contactez-nous
Nos experts en anticorps se tiennent à votre disposition et aimeraient en savoir plus sur vos besoins en matière de recherche. Les cibles difficiles sont les bienvenues !